The Retatrutide Integration Readiness Checklist: 12 Things Your Practice Must Have in Place Before the First Dose

Compliant integration of retatrutide into a clinical practice is not a single decision — it is a series of decisions and preparations that must be completed before any patient administration occurs. This checklist covers the 12 essential elements of a practice that is ready to engage with retatrutide in a legally defensible, clinically responsible way.

What it is: A formally approved research protocol from an accredited Institutional Review Board authorizing human administration of retatrutide in your practice.

Why it matters: Without IRB approval, there is no legal framework authorizing human administration of this investigational compound. Everything else on this list depends on this item being in place first.

Status check: Do you have a written IRB approval letter specifying the protocol number, the approved patient population, and the approval period?

What it is: An IRB-reviewed and approved informed consent document that covers all required elements for research involving investigational compounds.

Why it matters: A generic consent form does not meet the legal standard for informed consent in research. Your consent document must be the one approved by your IRB — not a modified version, not a template from another practice.

Status check: Is your consent document the exact version approved by your IRB, with the IRB approval stamp and date?

What it is: A licensed physician who is designated as the Principal Investigator for your research protocol and who has the clinical expertise to oversee retatrutide administration.

Why it matters: The IRB requires a qualified Principal Investigator. The medical director is responsible for clinical oversight, adverse event management, and protocol compliance.

Status check: Is your medical director named in the IRB protocol? Do they have documented training in human subjects research (e.g., CITI Program certification)?

What it is: A confirmed supply arrangement with a source that provides pharmaceutical-grade retatrutide with complete quality documentation — COAs covering identity, purity, potency, sterility, and endotoxin testing.

Why it matters: The quality of your supply determines the safety of your patients. A supplier who cannot provide complete COAs is not an appropriate source for a compound being administered to human patients.

Status check: Do you have a confirmed supply arrangement and a sample COA that covers all required quality parameters?

What it is: Appropriate refrigeration equipment with continuous temperature monitoring for retatrutide storage.

Why it matters: Temperature excursions degrade the compound and create patient safety risks. Your storage infrastructure must be capable of maintaining the required temperature range and documenting that it did so.

Status check: Do you have a calibrated refrigerator with a continuous temperature logger and a documented response procedure for temperature excursions?

What it is: A documented system for identifying, classifying, documenting, and reporting adverse events to your IRB on the required timeline.

Why it matters: Adverse event reporting is a regulatory obligation under your IRB protocol. A system that relies on memory or informal notes will fail.

Status check: Do you have an adverse event log, a clear internal process for who is responsible for reporting, and contact information for your IRB's adverse event reporting line?

What it is: A documented process for evaluating potential research subjects against your inclusion and exclusion criteria and recording the results.

Why it matters: If a patient who did not meet your inclusion criteria was enrolled, or a patient who met an exclusion criterion was not identified, that is a protocol deviation with legal implications.

Status check: Do you have a screening checklist that maps to your protocol's inclusion and exclusion criteria, and a process for documenting the screening results in each patient's research record?

What it is: A dedicated records system for your research study — separate from, but cross-referenced with, your clinical records.

Why it matters: Research records must be maintained for a minimum of three years after study completion. They must be organized, complete, and accessible for IRB audit.

Status check: Do you have a designated location (physical or electronic) for research records, with a retention policy that meets the regulatory minimum?

What it is: Written confirmation from your malpractice carrier that your policy covers IRB-approved research activities involving investigational compounds.

Why it matters: Many policies exclude research activities. Discovering a coverage gap after a claim is filed is not recoverable.

Status check: Do you have written confirmation from your carrier's underwriting department that your policy covers this activity?

What it is: Documented training for all staff involved in the research — on the protocol, the consent process, adverse event identification and reporting, and cold chain handling.

Why it matters: A protocol deviation caused by an untrained staff member is still a protocol deviation. The IRB holds the Principal Investigator responsible for the conduct of all study personnel.

Status check: Do you have training records for all staff involved in the study, including the date of training and the topics covered?

What it is: A review of your protocol, consent documents, and supply arrangements by a healthcare attorney familiar with FDA regulations and human subjects research.

Why it matters: The cost of a legal review before you start is a fraction of the cost of a medical board defense or malpractice litigation after something goes wrong.

Status check: Has a qualified healthcare attorney reviewed your protocol and consent documents and provided written feedback?

What it is: A documented process for identifying, documenting, and reporting protocol deviations to your IRB.

Why it matters: Protocol deviations will happen. The question is whether you have a process for managing them transparently or whether you are hoping they go unnoticed.

Status check: Do you have a protocol deviation log and a clear process for reporting deviations to your IRB within the required timeframe?

Work through this checklist before you administer the first dose. If any item is not in place, that item represents a gap in your compliance framework — and a potential liability exposure. Address each gap before proceeding.

This checklist is not exhaustive. Your specific IRB protocol may require additional elements. Your state's medical practice act may impose additional requirements. Your malpractice carrier may have additional documentation requirements. Use this checklist as a starting point, not a ceiling.

MedClinic Partners works with IRB-enrolled practices to provide research-grade supply and compliance support for retatrutide programs. If you are working through this checklist and need guidance on any item, reach out to our team.